|
 The potential vaccine is one of the two most advanced candidates
that BioNTech is working on with its partner Pfizer Inc <PFE.N> and
they received "fast track" status this week from the U.S. Food and
Drug Administration which is designed to speed up the regulatory
review process.
Fosun Pharma said in a filing that a unit will initiate a Phase I
clinical trial of BNT162b1 "as soon as possible once it is ready".
It is licensed to exclusively develop and commercialize COVID-19
vaccine products developed by using BioNTech's mRNA technology in
mainland China, Hong Kong, Macau and Taiwan.
The candidate is one of at least 23 being tested on humans in a
frantic global race to find a vaccine the world is counting on to
end a pandemic that has infected more than 13 million people and
killed more than half a million.
[to top of second column] |
Prior to the latest approval, Chinese researchers and companies have moved eight
vaccine candidates into different phases of human trials at home and abroad.
Fosun Pharma agreed in March to pay up to $85 million in licensing fees to use
BioNTech's proprietary mRNA technology and invest $50 million for a stake in the
German firm.
(Reporting by Roxanne Liu in Beijing and Twinnie Siu in Hong Kong; Editing by
Muralikumar Anantharaman and Edwina Gibbs)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
